Faber, Klaas Nico

Short Chain Fatty Acids (SCFAs)-Mediated Gut Epithelial and Immune Regulation and Its Relevance for Inflammatory Bowel Diseases

Parada Venegas, D., De la Fuente, M. K., Landskron, G., González, M. J., Quera, R., Dijkstra, G., Harmsen, H. J. M., Faber, K. N., & Hermoso, M. A. (2019) · Frontiers in Immunology

Gut microbiota and healthInflammatory Bowel Disease

Cited by 3,820

Altered Microbiota Diversity and Bile Acid Signaling in Cirrhotic and Noncirrhotic NASH-HCC

Sydor, S., Best, J., Messerschmidt, I., Manka, P., Vilchez-Vargas, R., Brodesser, S., Lucas, C., Wegehaupt, A., Wenning, C., Aßmuth, S., et al. (2020) · Clinical and Translational Gastroenterology

Gut microbiota and healthLiver Disease Diagnosis and Treatment

Cited by 127

Patients With Inflammatory Bowel Disease Show IgG Immune Responses Towards Specific Intestinal Bacterial Genera

Bourgonje, A. R., Roo-Brand, G., Lisotto, P., Sadaghian Sadabad, M., Reitsema, R. D., de Goffau, M. C., Faber, K. N., Dijkstra, G., & Harmsen, H. J. M. (2022) · Frontiers in Immunology

Gut microbiota and healthInflammatory Bowel Disease

Cited by 47

Liver organoids: established tools for disease modeling and drug development

Sun, X.-C., Kong, D.-F., Zhao, J., Faber, K. N., Xia, Q., & He, K. (2023) · Hepatology Communications

Liver physiology and pathologyDrug-Induced Hepatotoxicity and Protection

Cited by 37

High-throughput human microfluidic organoid-on-a-chip platform for modeling liver diseases and screening nanotherapeutics.

Kong, D., Yu, S., Heegsma, J., Blokzijl, T., Qin, T., Pan, Y., Blokzijl, H., de Meijer, V. E., Duan, Y., Faber, K. N., et al. (2026) · Journal of nanobiotechnology

3D Printing in Biomedical ResearchDrug-Induced Hepatotoxicity and Protection

Cited by 4